Φορτώνει......
Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
Αποθηκεύτηκε σε:
| Κύριος συγγραφέας: | |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Russo |
| Έκδοση: |
ABV-press
2021-09-01
|
| Σειρά: | Opuholi Ženskoj Reproduktivnoj Sistemy |
| Θέματα: | |
| Διαθέσιμο Online: | https://ojrs.abvpress.ru/ojrs/article/view/845 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|